We serve Chemical Name:6-Bromo-2,3,4,4a,9,9a-hexahydro-1H-carbazol-1-amine CAS:327990-62-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-Bromo-2,3,4,4a,9,9a-hexahydro-1H-carbazol-1-amine
CAS.NO:327990-62-5
Synonyms:6-bromo-2,3,3-trimethyl-3H-indole;3H-Indole,6-bromo-2,3,3-trimethyl;6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-amine
Molecular Formula:C12H15BrN2
Molecular Weight:267.16500
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:38.05000
Exact Mass:266.04200
LogP:3.67630
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 6-bromo-2,3,3-trimethyl-3H-indole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-bromo-2,3,3-trimethyl-3H-indole Use and application,6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-amine technical grade,usp/ep/jp grade.
Related News: The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. 6-Bromo-2,3,4,4a,9,9a-hexahydro-1H-carbazol-1-amine manufacturer The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations. 6-Bromo-2,3,4,4a,9,9a-hexahydro-1H-carbazol-1-amine supplier Production of J&J’s vaccine at the Baltimore site was halted by U.S. authorities in April and J&J was put in charge of manufacturing at the plant. 6-Bromo-2,3,4,4a,9,9a-hexahydro-1H-carbazol-1-amine vendor Production of J&J’s vaccine at the Baltimore site was halted by U.S. authorities in April and J&J was put in charge of manufacturing at the plant. 6-Bromo-2,3,4,4a,9,9a-hexahydro-1H-carbazol-1-amine factory The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.
